Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
intermittent claudication/obesitat
L'enllaç es desa al porta-retalls
Pàgina 1 des de 80 resultats
Changes in Function After a 6-Month Walking Intervention in Patients With Intermittent Claudication Who Are Obese or Nonobese.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
Both obesity and peripheral artery disease (PAD) limit function and may work additively to reduce mobility. The purpose of this study was to compare the effects of a 6-month, center-based walking program on mobility function between adults who are weight-stable obese and nonobese with
Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Obesity is recognized as an independent predictor of coronary artery disease; however, its importance in peripheral arterial disease is less clear. The aim of this study was to assess the association between obesity and the severity and outcome of intermittent claudication.
METHODS
This
Differences between women and men with intermittent claudication: a cross-sectional study.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Intermittent claudication (IC) and its consequences have customarily been underestimated in women. Our study aimed to determine the differences on functional and quality-of-life issues between women and men in a large group of claudicants.
METHODS
This study was an observational,
Prevalence of ischaemic heart disease, arterial hypertension and intermittent claudication, and distribution of risk factors among middle-aged men in Moscow and Berlin.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The initial examinations of prospective epidemiological studies of the same kind performed in random samples of 50-54 years old men from Moscow and Berlin showed the following prevalence rates (each first figure for Moscow, second for Berlin): ischaemic heart disease 14.4/13.6%, arterial
Impact of obesity on walking capacity and cardiovascular parameters in patients with peripheral artery disease: A cross-sectional study
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Background: Patients with peripheral artery disease (PAD) present a high prevalence of obesity and metabolic syndrome, as well as diseases related to cardiovascular dysfunction. However, whether obesity influences walking capacity and
[Lumbo-radicular pain caused by epidural lipomatosis in an obese patient: recovery after hypocaloric diet].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The case reported concerns an obese patient suffering from lumbo-radicular intermittent claudication due to lumbar epidural lipomatosis. Compression was revealed by magnetic resonance imaging which showed the existence of a hypersignal in weighted sequences in T1 situated in the epidural space and
A Retrospective Study of 6-Month Reduction in Risk of Developing Cardiovascular Diseases and Type 2 Diabetes Mellitus in Severely Obese Patients Over 60 Years of Age Following Bariatric Surgery.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND Controversy exists with regard to the effectiveness and reasons for bariatric procedures in patients older than 60 years. The goal of our study was to determine the reduction in risk of developing cardiovascular disease and type 2 diabetes mellitus after undergoing bariatric surgery in
Nutritional status and outcomes of superficial femoral artery stenting due to intermittent claudication.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Analysis of hemodynamics and angiogenic response to ischemia in the obese type 2 diabetic model Spontaneously Diabetic Torii Leprfa (SDT fatty) rats.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Peripheral artery disease (PAD) is defined as peripheral blood flow impairment, especially in the legs, caused by atherosclerotic stenosis. The disease decreases quality of life because of intermittent claudication or necrosis of the leg. The hindlimb ischemia model, in which ischemia is induced by
An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
A randomized placebo-controlled study was undertaken in 188 patients with severe intermittent claudication attending two vascular clinics in Manchester and Liverpool. After a 4-week run-in period, patients received active or placebo treatment for 24 weeks. Patients were assessed on a treadmill prior
Peripheral arterial disease and intermittent claudication in coronary heart disease patients
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Background and aim: Peripheral artery disease (PAD) is associated with an increased risk of fatal and non-fatal coronary heart disease (CHD). The aims of the this study were 1) to investigate the prevalence of PAD and suspected PAD in a
The prognostic impact of general and abdominal obesity in peripheral arterial disease.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
Obesity is an independent cardiovascular risk factor, but its prognostic role in patients with peripheral arterial disease (PAD) is not well defined. Accordingly, we assessed the impact of body mass index (BMI) and waist circumference (WC) on cardiovascular risk in a homogeneous cohort of
Unbalanced risk factors, could compromise the effectiveness of physical training in patients with intermittent claudication?
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
The correction of atherosclerotic risk factors is the unavoidable assumption to assure the maximal effectiveness and duration of the results of any therapeutic intervention (pharmacological and surgical) for the treatment of intermittent claudication. Aim of this study has been to verify
Differences In Anthropometric Measures Between Critical Limb Threatening Ischaemia And Intermittent Claudication In Patients Undergoing Aorto Bifemoral Bypass
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Objective/background: Peripheral artery disease (PAD) is an important manifestation of systemic atherosclerosis. Obesity is a risk factor for atherosclerosis and for cardiovascular events. However, the relationship between obesity and PAD
Gender and ethnic differences in arterial compliance in patients with intermittent claudication.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
To assess the gender and ethnic differences in arterial compliance in patients with intermittent claudication.
METHODS
A total of 114 patients participated, including 38 Caucasian men, 32 Caucasian women, 16 African American men, and 28 African American women. Patients were assessed on
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
